Published in Hepatitis Weekly, September 30th, 2002
"We have moved aggressively to reacquire full rights to our products not only because of our enthusiasm for the compounds but also because we believe this is a win-win outcome for Triangle and Abbott," said Chris Rallis, president and chief operating officer of Triangle. "For Triangle, we believe that the reacquisition of the rights to Coviracil, amdoxovir, and clevudine, all currently in clinical development, allows us...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly